LONDON: Researchers are development a
young drug that will treat heart disease and angina pectoris without exacerbating any
inherent respiratory problems.
The University of Nottingham
researchers have already developed a molecule that is much more efficient at
discriminating between the heart and lungs than current drugs, EurekaAlert
reported Friday.
Researchers will be carrying out further studies to
improve the molecule to ensure that it is able to target the heart cells more
efficaciously - leaving the lungs untouched.
Jill Baker from the
University's School of Biomedical Sciences, world Health Organization is ahead the research, said:
"Once developed, this molecule will causal agent much less wheezing and shortness of
breath and should be able to be minded safely to the hundreds of thousands of
patients with both heart and lung diseases".
Doctors are extremely
leery of prescribing beta-blockers for patients suffering from spunk disease and
chronic impeding pulmonary disease (COPD), which aggravate respiratory
symptoms. COPD causes the destruction of lung tissue and increased mucus
production.
More information
